RVMD

Revolution Medicines is, in its own words, "a clinical-stage precision oncology company with a limited operating history and no products approved for commercial sale." The financials confirm it: product revenue was $0.00 in both FY2024 and FY2025, the net loss widened to -$1.13B (from -$600M), and the accumulated deficit now stands at -$2.87B. R&D spending jumped 66.7% to $987M as the company pushes its RAS(ON) pipeline forward. There is no fundamentals-based valuation case here — diluted EPS is -$5.95 and ROE is -69.3% by design. This is a binary clinical bet, not a profitable business.

The balance sheet is the near-term pressure point. Operating cash flow was -$898M, while cash & equivalents fell 29.3% to just $384M. Current assets of $2.08B (which include marketable securities) imply only roughly two years of runway at the current burn — so further capital raises are effectively certain, and shares already rose 6.6% YoY, signaling dilution underway. Total liabilities surged 146.7% to $723M (the filing attributes funding partly to a Royalty Purchase Agreement), layering financing obligations onto a company with no product sales; liabilities/equity is still a manageable 0.44x, but that ratio flatters a pre-revenue burn machine.